Lilly reports Phase II NSCLC data for ramucirumab

Eli Lilly and Co. (NYSE:LLY) reported data from a pair of open-label Phase II trials of ramucirumab to treat advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology meeting in Vienna. In 140 evaluable chemotherapy-naïve patients with advanced non-squamous NSCLC, ramucirumab plus Alimta pemetrexed and carboplatin or cisplatin led to a median progression-free survival of 6.3 months vs. 4.3 months for Alimta plus carboplatin or cisplatin. The disease control rate (DCR) in the ramucirumab arm was 87% vs. 72% in the control arm. Enrollment of chemotherapy-naïve patients with advanced squamous NSCLC in the Phase II trial is ongoing with data expected next year. ...